Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Public ClinicalTrials.gov record NCT00501735. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma
Study identification
- NCT ID
- NCT00501735
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Enrollment
- 144 participants
Conditions and interventions
Conditions
Interventions
- Forodesine 200 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2007
- Primary completion
- Jun 30, 2010
- Completion
- Nov 30, 2011
- Last update posted
- Jan 22, 2012
2007 – 2011
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham, Comprehensive Cancer Ctr | Birmingham | Alabama | 35294-3300 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| LSU Health Sciences Center, Feist-Weiller Cancer Center | Shreveport | Louisiana | 71103 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Hackensack University Medical Ctr | Hackensack | New Jersey | 07601 | — |
| Upstate Medical University | Syracuse | New York | 13210 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Wake Forest University Health Sceinces, Dept. of Dermatology | Winston-Salem | North Carolina | 27157 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| University Hospitals Case Medical Center, Dept. of Dermatology | Cleveland | Ohio | 44106 | — |
| Hospital at the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Hillman Cancer Ctr., University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| M.D. Anderson Cancer Center - Dermatology | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 89109 | — |
| University of Wisconsin-Madison, Dept of Dermatology | Madison | Wisconsin | 53715 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00501735, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 22, 2012 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00501735 live on ClinicalTrials.gov.